Company profile
Design Therapeutics, Inc.
NASDAQ: DSGN · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
55CFH 63DQ 44GM —SS 51
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$69.8M
Employees
55
as of 2026-08-10
Market cap
$873.8M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$69.8M-$69.8M2025
Operating income-$79.5M-$79.5M2025
Total assets$226.2M$226.2M2025
Liabilities$13.7M$13.7M2025
Equity$212.5M$212.5M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Design Therapeutics, Inc.’s revenue?
Design Therapeutics, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Rest Ez Inc.——Kardigan, Inc.——Cullinan Therapeutics, Inc.50DMonopar Therapeutics Inc.59CAllogene Therapeutics, Inc.39DAchieve Life Sciences, Inc.37DNeighbors
San Diego →Key facts
CEOPratik Shah
SectorHealthcare
IndustryBiotechnology
HeadquartersCarlsbad, CA
ExchangeNASDAQ: DSGN
Employees55
IPO date2021-03-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.